期刊
INTERNATIONAL JOURNAL OF CANCER
卷 128, 期 10, 页码 2453-2462出版社
WILEY-BLACKWELL
DOI: 10.1002/ijc.25563
关键词
bone metastases; integrins; osteolysis; volumetric computed tomography; dynamic contrast-enhanced MRI
类别
资金
- Deutsche Forschungsgemeinschaft [SFB-TR23]
- Merck-Serono
The aim of this study was to investigate the effect of inhibiting alpha(v)beta(3)/alpha(v)beta(5) integrins by cilengitide in experimentally induced breast cancer bone metastases using noninvasive imaging techniques. For this purpose, nude rats bearing established breast cancer bone metastases were treated with cilengitide, a small molecule inhibitor of alpha(v)beta(3) and alpha(v)beta(5) integrins (75 mg/kg, five days per week; n = 12 rats) and compared to vehicle-treated control rats (n = 12). In a longitudinal study, conventional magnetic resonance imaging (MRI) and flat panel volumetric computed tomography were used to assess the volume of the soft tissue tumor and osteolysis, respectively, and dynamic contrast-enhanced (DCE-) MRI was performed to determine functional parameters of the tumor vasculature reflecting blood volume and blood vessel permeability. In rats treated with cilengitide, VCT and MRI showed that osteolytic lesions and the respective bone metastatic soft tissue tumors progressed more slowly than in vehicle-treated controls. DCE-MRI indicated a decrease in blood volume and an increase in vessel permeability and immunohistology revealed increased numbers of immature vessels in cilengitide-treated rats compared to vehicle controls. In conclusion, treatment of experimental breast cancer bone metastases with cilengitide resulted in pronounced antiresorptive and antitumor effects, suggesting that alpha(v)beta(3)/alpha(v)beta(5) inhibition may be a promising therapeutic approach for bone metastases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据